Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai HeartCare Medical Technology Corporation Limited (6609.HK)
Shanghai, CN
Shanghai HeartCare Medical Technology Corporation Limited is a global enterprise specializing in the research, development, manufacturing, and commercialization of neuro-interventional medical devices. Its extensive product range encompasses devices for ischemic stroke thrombectomy, intracranial stenosis intervention, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access. These medical technologies are utilized for both the prevention and treatment of ischemic stroke, including acute ischemic events and intracranial narrowing, as well as for addressing hemorrhagic stroke. Established in 2016 and previously operating as Shanghai Care Medical Technology Corporation Limited, the company maintains its headquarters in Shanghai, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.33% | -0.85% | -14.02% | +3.60% | -1.48% | -13.22% | +62.09% | +22.31% | -63.88% | -63.88% | -63.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-09 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+46.9% ★ Q4'25: +49.1% (vs Q4'24)
-
EPS growth Medical - Devices: +28.5%+711.1% ★ Q4'25: +490.9% (vs Q4'24)
-
FCF margin FCF growth · Medical - Devices: +30.9%+18.8% Q4'25: +20.5% (vs Q4'24)
-
EBIT margin Medical - Devices: +6.2%+10.8% ★ Q4'25: +10.1% (vs Q4'24)
-
ROIC Medical - Devices: +3.3%+11.0% ★ Q4'25: +10.1% (vs Q4'24)
-
Share dilution Medical - Devices: 0.0%+0.5% Q4'25: -0.3% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.66× ★ Q4'25: 0.67× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
90.09M
est: 90.41M (-0.4%)
|
183.03M
est: 176.55M (+3.7%)
|
232.34M
est: 233.71M (-0.6%)
|
277.90M
est: 299.89M (-7.3%)
|
408.29M
est: 401.86M (+1.6%)
|
552.01M
552.01M – 552.01M
+37.4% YoY
|
734.25M
734.25M – 734.25M
+33.0% YoY
|
1.02B
1.02B – 1.02B
+38.4% YoY
|
| EBITDA |
-183.34M
est: -56.60M (-223.9%)
|
-167.31M
est: -110.53M (-51.4%)
|
-68.50M
est: -92.20M (+25.7%)
|
21.87M
est: -118.30M (+118.5%)
|
64.43M
est: -158.53M (+140.6%)
|
-217.77M
-217.77M – -217.77M
-37.4% YoY
|
-289.66M
-289.66M – -289.66M
-33.0% YoY
|
-400.87M
-400.87M – -400.87M
-38.4% YoY
|
| EBIT |
-195.54M
est: -62.75M (-211.6%)
|
-199.10M
est: -122.55M (-62.5%)
|
-100.76M
est: -110.41M (+8.7%)
|
-10.24M
est: -141.67M (+92.8%)
|
44.27M
est: -189.85M (+123.3%)
|
-260.78M
-260.78M – -260.78M
-37.4% YoY
|
-346.88M
-346.88M – -346.88M
-33.0% YoY
|
-480.05M
-480.05M – -480.05M
-38.4% YoY
|
| Net Income |
-194.23M
est: -185.34M (-4.8%)
|
-200.38M
est: -148.29M (-35.1%)
|
-94.01M
est: -41.73M (-125.3%)
|
-13.62M
est: 758.7K (-1,895.5%)
|
83.34M
est: 69.04M (+20.7%)
|
108.79M
108.79M – 108.79M
+57.6% YoY
|
160.96M
160.96M – 160.96M
+48.0% YoY
|
221.04M
221.04M – 221.04M
+37.3% YoY
|
| SGA |
167.02M
est: 122.75M (+36.1%)
|
167.99M
est: 239.72M (-29.9%)
|
153.88M
est: 205.11M (-25.0%)
|
137.81M
est: 263.20M (-47.6%)
|
187.12M
est: 352.69M (-46.9%)
|
484.47M
484.47M – 484.47M
+37.4% YoY
|
644.41M
644.41M – 644.41M
+33.0% YoY
|
891.82M
891.82M – 891.82M
+38.4% YoY
|
| EPS |
-5.82
est: -4.91 (-18.6%)
|
-5.24
est: -3.93 (-33.5%)
|
-2.47
est: -1.10 (-124.6%)
|
-0.36
est: 0.02 (-1,900.7%)
|
2.21
est: 1.82 (+21.5%)
|
2.87
2.87 – 2.87
+57.6% YoY
|
4.24
4.24 – 4.24
+48.0% YoY
|
5.82
5.82 – 5.82
+37.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guohui Wang | Chairman & Chief Executive Officer | 2M | male |
| Jiawei Wei | Senior VP, Chief Marketing Officer, Deputy GM & Executive Director | 1M | male |
| Kun Zhang | Executive Director | 822.8K | female |
| Han Zhang | COO, CFO & Joint Company Secretary | — | male |
| Siu Ying Kwok | Joint Company Secretary | — | female |
| Zongyu Xue | Senior Vice President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6609.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
